880870-13-3

Basic information

• Product Name: 5-BROMO-2-CHLORO-4-METHOXYPYRIDINE
• Synonyms: 5-BROMO-2-CHLORO-4-METHOXYPYRIDINE
• CAS NO: 880870-13-3
• Molecular Formula: C₆H₅BrClNO
• Molecular Weight: 222.47
• Mol File: 880870-13-3.mol

Chemical Properties

• Boiling Point: 251℃
• Flash Point: 105℃
• Appearance: /
• Density: 1.650
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.14±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-2-CHLORO-4-METHOXYPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-CHLORO-4-METHOXYPYRIDINE(880870-13-3)
• EPA Substance Registry System: 5-BROMO-2-CHLORO-4-METHOXYPYRIDINE(880870-13-3)

Safety Data

• Hazardous Substances Data: 880870-13-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
5-Bromo-2-chloro-4-methoxypyridine is utilized as an intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs due to its versatile chemical properties and reactivity.
Used in Agrochemical Production:
In the agrochemical industry, 5-Bromo-2-chloro-4-methoxypyridine serves as an intermediate, playing a crucial role in the creation of various agrochemicals that are essential for crop protection and enhancement of agricultural yields.
Used in Organic Synthesis Research:
5-Bromo-2-chloro-4-methoxypyridine is employed as a reagent in research and industrial laboratories. Its potential applications in the development of new compounds make it a valuable asset for scientists working on advancing organic synthesis techniques and discovering novel organic compounds.

Upstream product

• 17228-69-2 2-chloro-4-methoxy-pyridine 
• 849937-96-8 5-bromo-2,4,-dichloropyridine 
• 124-41-4 sodium methylate 

Downstream Products

• 1256823-05-8 6-chloro-4-methoxypyridine-3-carbaldehyde 
• 1196146-82-3 5-bromo-2-chloro-pyridin-4-ol 
• 1187190-69-7 6-chloro-4-methoxypyridine-3-carbonitrile 
• 880870-14-4 C₁₃H₁₀Cl₂FNO 

Relevant articles and documents

PLASMA KALLIKREIN INHIBITORS AND USES THEREOF

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

D-AMINO ACID OXIDASE ACTIVITY INHIBITING COMPOUNDS

Compounds of formula (I), wherein R1 through R3 are as defined in the claims, or pharmaceutically acceptable esters, salts, hydrates or solvates thereof, useful as DAAO inhibitors as well as pharmaceutical compositions containing the

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Inhibitors of the renal outer medullary potassium channel

This invention relates to compounds of Formula I having the following general structure: [in-line-formulae]Z1—Y1—(CH2)n1—R—(CH2)n2—Y2—Z2 [/in-line-formulae] wherein R

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

This invention relates to compounds of Formula I-VI having the following general structure: wherein R is a 6-8 membered saturated heterocyclic ring having 2 Nitrogen atoms connected with (CH2)n1- and (CH2)n2-, respectively, and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

This invention relates to compounds of Formula I having the following general structure: wherein R represents a fused bicyclic or spirocyclic aliphatic diamine and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary